MX2020001046A - Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. - Google Patents
Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.Info
- Publication number
- MX2020001046A MX2020001046A MX2020001046A MX2020001046A MX2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic composition
- peptide derived
- fusion peptide
- superantigen
- toxoids
- Prior art date
Links
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 title abstract 3
- 231100000617 superantigen Toxicity 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537706P | 2017-07-27 | 2017-07-27 | |
| PCT/US2018/043687 WO2019023341A1 (en) | 2017-07-27 | 2018-07-25 | IMMUNOGENIC COMPOSITION COMPRISING A MELTING PEPTIDE DERIVED FROM TOXOIDS OF SUPERANTIGENES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001046A true MX2020001046A (es) | 2020-08-06 |
Family
ID=65041106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001046A MX2020001046A (es) | 2017-07-27 | 2018-07-25 | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11260120B2 (https=) |
| EP (1) | EP3658181A4 (https=) |
| JP (1) | JP7303791B2 (https=) |
| CN (1) | CN110996993B (https=) |
| CA (1) | CA3069747A1 (https=) |
| MX (1) | MX2020001046A (https=) |
| WO (1) | WO2019023341A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116497003A (zh) * | 2023-06-29 | 2023-07-28 | 北京百普赛斯生物科技股份有限公司 | 一种从溶液中纯化目标蛋白的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593114B1 (en) | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| CA2337966A1 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Vaccine against staphylococcus intoxication |
| SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| WO2003056015A1 (en) | 2001-11-26 | 2003-07-10 | U.S. Medical Research Institute Of Infectious Diseases | Bacterial superantigen vaccines |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| US7754225B2 (en) | 2006-07-20 | 2010-07-13 | Glaxosmithkline Biologicals S.A. | Method of protecting against staphylococcal infection |
| WO2008154101A1 (en) | 2007-06-06 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
| JP5658564B2 (ja) | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| AU2012214677B2 (en) | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| AU2012266880A1 (en) | 2011-03-16 | 2013-10-03 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| EP2785368B1 (en) | 2011-12-02 | 2019-03-13 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
| EP3010535B1 (en) * | 2013-06-19 | 2019-08-14 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
-
2018
- 2018-07-25 JP JP2020503935A patent/JP7303791B2/ja active Active
- 2018-07-25 MX MX2020001046A patent/MX2020001046A/es unknown
- 2018-07-25 CA CA3069747A patent/CA3069747A1/en active Pending
- 2018-07-25 WO PCT/US2018/043687 patent/WO2019023341A1/en not_active Ceased
- 2018-07-25 US US16/633,664 patent/US11260120B2/en active Active
- 2018-07-25 EP EP18838475.4A patent/EP3658181A4/en active Pending
- 2018-07-25 CN CN201880047111.4A patent/CN110996993B/zh active Active
-
2022
- 2022-02-25 US US17/680,897 patent/US11826412B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019023341A1 (en) | 2019-01-31 |
| US20200206335A1 (en) | 2020-07-02 |
| JP7303791B2 (ja) | 2023-07-05 |
| JP2020537488A (ja) | 2020-12-24 |
| US20220257744A1 (en) | 2022-08-18 |
| US11260120B2 (en) | 2022-03-01 |
| CN110996993A (zh) | 2020-04-10 |
| EP3658181A1 (en) | 2020-06-03 |
| CN110996993B (zh) | 2024-05-31 |
| CA3069747A1 (en) | 2019-01-31 |
| US11826412B2 (en) | 2023-11-28 |
| EP3658181A4 (en) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| AU2018243910A8 (en) | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof | |
| WO2020039359A3 (en) | Escherichia coli compositions and methods thereof | |
| MX2020005170A (es) | Formulaciones de proteinas de fusion vegfr-fc. | |
| WO2020008377A3 (en) | Ionic self-assembling peptides | |
| EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
| MX2020006328A (es) | Composición inmunogénica. | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| MX388814B (es) | Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo. | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| WO2015031778A3 (en) | Compositions and methods for the treatment or prevention of tuberculosis | |
| MX2021002909A (es) | Vacunas de proteinas de fusion neumococicas. | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| MX2019015007A (es) | Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
| GB2568440A (en) | Modified factor H binding protein | |
| EA201990451A1 (ru) | Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение | |
| ZA202202180B (en) | Engineered hcv e2 immunogens and related vaccine compositions | |
| MX362058B (es) | Péptido pntx(19) sintético, composición farmacéutica y uso. | |
| MX2017015375A (es) | Variantes de oxintomodulina pegilada. | |
| MX2020001046A (es) | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. | |
| MX2015013808A (es) | Vacuna contra garrapatas rhipicephalus. | |
| MX2022004061A (es) | Peptidos de estafilococo y metodos de uso. | |
| IL270917A (en) | Recombinant ROBO2 proteins, preparations, methods and their use | |
| MX2018012270A (es) | Novedosas formulaciones de vacuna neumococica. |